Literature DB >> 9259356

Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.

A B Chapman1, A M Johnson, S Rainguet, K Hossack, P Gabow, R W Schrier.   

Abstract

Cardiovascular complications are the most common cause of morbidity and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD). To understand this relationship, known cardiovascular risk factors were examined in ADPKD. Left ventricular hypertrophy (LVH) is a known, important risk factor for premature cardiovascular death in patients with essential hypertension. Hypertension is known to occur frequently and early in ADPKD patients. The frequency of LVH in ADPKD patients and its relation with hypertension and other risk factors, however, is not known. In this study, echocardiographic tests were performed in 116 consecutive adult ADPKD patients and 77 healthy control subjects. There was a significantly higher frequency of LVH in ADPKD men (46 versus 20%, P < 0.05) and women (37 versus 12%, P < 0.005) compared with control subjects. LVH in ADPKD patients was associated with higher systolic and diastolic arterial BP. There also was an association between LVH, diminished renal function, and increased renal volume. When comparing ADPKD patients with and without LVH, the former were older, weighed more, had a higher prevalence of hypertension, and had a lower hematocrit value and more renal impairment. LVH was also present in 23% of normotensive ADPKD patients and 16% of healthy control subjects (P = NS), but did not correlate with BP. The role of BP as a contributing factor to LVH in ADPKD patients may be due in part to earlier onset and inadequate treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9259356     DOI: 10.1681/ASN.V881292

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  48 in total

1.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

Review 4.  ADPKD: molecular characterization and quest for treatment.

Authors:  Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

5.  Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors.

Authors:  Erica Allen; Klaus B Piontek; Elizabeth Garrett-Mayer; Miguel Garcia-Gonzalez; Kerry Lee Gorelick; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2005-11-21       Impact factor: 6.150

6.  Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.

Authors:  Bjarne Orskov; Vibeke Rømming Sørensen; Bo Feldt-Rasmussen; Svend Strandgaard
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

7.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

8.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

9.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

10.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.